Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.41 |
| ▸ | MTOR | P42345 | 4/20 | 0.39 |
| ▸ | RICTOR | Q6R327 | 4/20 | 0.39 |
| ▸ | RPTOR | Q8N122 | 4/20 | 0.39 |
| ▸ | MAPKAP1 | Q9BPZ7 | 4/20 | 0.39 |
| ▸ | MLST8 | Q9BVC4 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
| ▸ | SMAD2 | Q15796 | 1/20 | 0.36 |
| ▸ | VRK1 | Q99986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4265699 | 0.70 | PIK3CD (0.52) | TGFBR1MTORPIK3CA | |
| SCHEMBL4267729 | 0.70 | KDR (0.53) | DYRK1ATGFBR1MTORPIK3CA | |
| SCHEMBL7997101 | 0.69 | SRC (0.69) | MTORRICTORRPTORMAPKAP1MLST8 | |
| SCHEMBL4264882 | 0.67 | EGFR (0.48) | MTORPIK3CA | |
| Hydrochloric Acid SCHEMBL4532456 | 0.66 | DYRK1A (0.54) | DYRK1ATGFBR1BMPR1ASMAD2VRK1 | |
| SCHEMBL20600762 | 0.66 | DYRK1A (0.50) | DYRK1ATGFBR1BMPR1ASMAD2VRK1 | |
| SCHEMBL30945399 | 0.66 | DYRK1A (0.56) | DYRK1ATGFBR1BMPR1ASMAD2VRK1 | |
| SCHEMBL29754568 | 0.66 | DYRK1A (0.56) | DYRK1ATGFBR1BMPR1ASMAD2VRK1 | |
| SCHEMBL4269315 | 0.65 | SRC (0.52) | MTORPIK3CA | |
| SCHEMBL31214345 | 0.65 | DYRK1A (0.72) | DYRK1ATGFBR1MTORPIK3CABMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | claimed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | claimed |
| US-8314234-B2 | Bicyclic pyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-11-20 | — | — | US | disclosed |
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008039359-A2 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076037-A1 | BICYCLIC PYRIMIDINE KINASE INHIBITORS | DCK, CDK2, DTYMK | DYRK1A 1042/4885TGFBR1 3133/4885MTOR 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.